
Bayer Sevabertinib gets USFDA Priority Review status for HER2-mutant non-small cell lung cancer
Berlin: Bayer has received Priority Review status from the US Food and Drug Administration (FDA) for the investigational compound sevabertinib (BAY 2927088) for the treatment of adult patients with advanced non-small cell lung cancer (NSCLC) whose tumors …